Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Bimzelx Tops Skyrizi in Head-to-Head Psoriatic Arthritis Trial

Summary by biopharmadive.com
UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.

2 Articles

biopharmadive.combiopharmadive.com
Center

Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial

UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.

Read Full Article
pharmatimes.compharmatimes.com

UCB reports superiority of bimekizumab in psoriatic arthritis study

BE BOLD trial shows bimekizumab outperforms risankizumab at Week 16

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

pharmatimes.com broke the news in on Wednesday, March 11, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal